CurrentCignaPolicy N/A

Antiseizure Medications - Vigabatrin Prior Authorization Policy

Cigna prior authorization policy governing coverage of vigabatrin products (Sabril, Vigpoder, Vigadrone, Vigafyde) for FDA-approved indications and other supported uses, including required prescriber specialty, age limits, prior medication trials, approval durations, monitoring expectations, and non-covered uses.

Policy Summary

PayerCigna

PolicyAntiseizure Medications - Vigabatrin Prior Authorization Policy

Policy CodePolicy N/A

Change TypeTerminology updatesadded branded genericsno clinical criteria changes

Effective Date

Next Review Date

Key ActionObtain prior authorization and document prescriber specialty, prior antiseizure medication trials (when applicable), and vision monitoring per policy requirements.

SourceLink

POLICY UPDATE CHANGES

Policy name changed from Antiepileptics - Vigabatrin Prior Authorization Policy to Antiseizure Medications - Vigabatrin Prior Authorization Policy; references to antiepileptic medications were changed to antiseizure medications.

Vigpoder and Vigadrone (branded generics) were rolled into the policy.

Vigafyde was added to the policy.

Annual Revision on 04/23/2025 indicated 'No criteria changes.'

2Covered Indications

4Listed product brands/generics

3Approval durations (months)

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Summary

Overview: This policy governs prior authorization for vigabatrin products (Sabril, Vigpoder, Vigadrone, Vigafyde) and covers FDA‑approved uses with defined clinical criteria. Coverage stance: covered_with_criteria — products are covered when the specified criteria are met.

Key stats: • Covered indications: 2 (Infantile spasms; Treatment‑refractory complex partial seizures). • Products listed: 4 (Sabril, Vigpoder, Vigadrone, Vigafyde).

Key Eligibility Thresholds

Infantile spasms age≤ 2 years

Complex partial seizures age≥ 2 years

Prior antiseizure medication trials≥ 3 other antiseizure medications

Boxed warning/REMS and monitoring: Vigabatrin carries a Boxed Warning for permanent vision loss and is available only through the Vigabatrin REMS Program. Vision assessment is recommended at baseline (no later than 4 weeks after starting), at least every 3 months during therapy, and about 3–6 months after discontinuation; vision loss, once detected, is irreversible. The policy expects documentation of monitoring given the REMS and vision‑loss risk.

Medical-Necessity Criteria

Provider Actions & Documentation Requirements

Prior Authorization

Prior authorization required

Prior authorization is required for prescription benefit coverage of vigabatrin. Approvals are provided for specified durations depending on the indication.

Infantile spasms: Approve for 6 months
Initial therapy for refractory complex partial seizures: Approve for 3 months
Current users responding to therapy: Approve for 1 year

Documentation Required

Prescriber specialty documentation

Document that vigabatrin is prescribed by or in consultation with a neurologist or a physician who specializes in the condition being treated.

Coding

Products coveredmixedCovered

Sabril	vigabatrin tablets and powder for solution - Lundbeck (brand name listed)
Vigpoder	vigabatrin powder for oral solution - Pyros (branded generic)
Vigadrone	vigabatrin tablets and oral solution - Upsher-Smith (branded generic)
Vigafyde	vigabatrin oral solution - Pyros

Background

Background and indications: Vigabatrin is indicated as monotherapy for infantile spasms in patients 1 month to 2 years of age and as adjunctive therapy for refractory complex partial seizures in patients ≥ 2 years who have inadequately responded to several alternative treatments. It is not a first‑line agent for complex partial seizures and should be used when benefits outweigh the risk of vision loss.

Boxed warning and REMS: Vigabatrin has a Boxed Warning for permanent vision loss; onset is unpredictable and may occur within weeks or after long exposure. Because of this risk, vigabatrin is available only through a restricted access program under the Vigabatrin REMS Program.

Dosing and withdrawal guidance: Prescribing information advises using the lowest effective dose and shortest exposure consistent with clinical objectives. Withdraw vigabatrin if no substantial clinical benefit is observed within 2–4 weeks for infantile spasms and within 3 months for refractory complex partial seizures.

Vision monitoring recommendationBaseline (no later than 4 weeks after start), at least every 3 months during therapy, and about 3–6 months after discontinuation

Withdrawal if no benefitInfantile spasms: 2–4 weeks; Refractory complex partial seizures: 3 months

Definitions:

Revision History

09/20/2023terminology update

Policy name changed from 'Antiepileptics - Vigabatrin Prior Authorization Policy' to 'Antiseizure Medications - Vigabatrin Prior Authorization Policy' and references to antiepileptic medications were changed to antiseizure medications (annual revision).

04/19/2024inclusion

Vigpoder (branded generic) and Vigadrone (branded generic) were rolled into the policy.

09/18/2024addition

Policy Summary

PayerCigna

PolicyAntiseizure Medications - Vigabatrin Prior Authorization Policy

Policy CodePolicy N/A

Change TypeTerminology updatesadded branded genericsno clinical criteria changes

Effective Date

Next Review Date

Key ActionObtain prior authorization and document prescriber specialty, prior antiseizure medication trials (when applicable), and vision monitoring per policy requirements.

SourceLink

On This Page

Documentation Required

Prior treatment documentation for refractory complex partial seizures

For initial therapy approval for refractory complex partial seizures, document trial and/or concomitant use of at least three other antiseizure medications.

Document trial and/or concomitant use of ≥3 other antiseizure medications

Documentation Required

Monitoring requirement (clinical expectation)

Because of the boxed warning for permanent vision loss and REMS requirements, document vision assessments per the recommended schedule.

Baseline vision assessment no later than 4 weeks after starting therapy
Vision assessment at least every 3 months during therapy
Vision assessment about 3 to 6 months after discontinuation

Denial Risk

Denial if used outside criteria

Claims will be denied as not covered when billed for conditions or diagnoses not specified as covered indications under this policy.

• Monotherapy: Use of vigabatrin as the sole antiseizure medication for the indicated condition (required for infantile spasms).

• Treatment‑refractory complex partial seizures: Complex partial seizures in patients ≥ 2 years who have inadequately responded to several alternative treatments; initial therapy approval requires trial and/or concomitant use of ≥ 3 other antiseizure medications.

Vigafyde (vigabatrin oral solution) was added to the policy.

04/23/2025annual reviewLatest

Annual revision noted: No criteria changes.